Here are three things to know.
1. Glatopa, manufactured by Novartis’ subsidiary Sandoz, is intended for patients with relapsing forms of multiple sclerosis. The drug is administered as an injection three times a week.
2. Sandoz earned FDA approval for a smaller dosage of Glatopa in 2015. Contamination issues at a production plant delayed regulatory approval of the new dosage form until this month.
3. Glatopa represents the second generic version of Teva’s brand-name drug to enter the market. Mylan launched its version in 2017.
More articles on supply chain:
FDA OKs Novartis’ generic version of Teva’s MS drug: 3 things to know
Walgreens is reportedly in talks to purchase AmerisourceBergen: 7 things to know
Philips recalls HeartStart MRx Defibrillator: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
